Doliver Advisors LP purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund purchased 30,000 shares of the company’s stock, valued at approximately $551,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VRDN. Perceptive Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 108.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after purchasing an additional 1,580,303 shares in the last quarter. Jennison Associates LLC purchased a new position in shares of Viridian Therapeutics during the fourth quarter valued at $35,915,000. Avoro Capital Advisors LLC acquired a new position in Viridian Therapeutics during the fourth quarter valued at $46,680,000. Vanguard Group Inc. raised its position in Viridian Therapeutics by 29.6% during the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after buying an additional 1,280,161 shares during the period. Finally, Privium Fund Management B.V. purchased a new stake in Viridian Therapeutics in the 4th quarter worth about $5,400,000.
Viridian Therapeutics Stock Down 0.4%
Shares of Viridian Therapeutics stock opened at $22.97 on Wednesday. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -6.82 and a beta of 0.91. The stock has a 50-day simple moving average of $18.65 and a 200-day simple moving average of $21.45. Viridian Therapeutics, Inc. has a 52-week low of $13.18 and a 52-week high of $34.29. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15.
Analysts Set New Price Targets
Several research firms have weighed in on VRDN. Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Wells Fargo & Company raised shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $20.00 to $31.00 in a research report on Monday, June 29th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a report on Monday, June 29th. Evercore set a $26.00 price objective on shares of Viridian Therapeutics in a research report on Friday, May 15th. Finally, Wedbush upped their price objective on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.93.
View Our Latest Stock Report on VRDN
Viridian Therapeutics Profile
Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.
In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.
Featured Articles
- Five stocks we like better than Viridian Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report).
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
